News

India has announced plans for a new short-term strategy aimed at boosting pharmaceutical exports, and has also set guidelines for domestic drugmakers to comply with a European Union (EU) directive on imports of bulk drugs into Europe.

Cost regulators for the National Health Service in England and Wales have issued final guidance recommending Novartis’ Lucentis as a treatment for a common eye condition called macular oedema.

Twice as many patients with non-Hodgkin’s lymphoma (NHL) are hitting a post-diagnosis survival marker than in the 1970’s, a report by Cancer Research and the Haematological Malignancy Research Network has found.  

Pharma spending on US doctors topped $1 billion last year as the industry braces for the arrival of the Sunshine Act.

Around 20% of clinical trials currently underway are using adaptive designs, while adoption of these techniques is likely to increase significantly over the next few years, particularly in the exploratory phase of drug development, a new report suggests.

Valeant Pharmaceuticals has acquired the eye health company Bausch & Lomb for $8.7 billion in cash.

GeneWatch UK says the UK Government’s is looking to build a DNA database by stealth in the NHS in England, according to a new report.

Johnson & Johnson says it is looking to have ten new pharma products on the market in the next four years as it looks to build on a strong 2012.

New survey of NHS professionals finds a vast majority do not believe that quality of care in the health service is given enough priority.

Healthcare organisations expanding into emerging markets like Brazil, Russia, India and China (BRIC) are now realising that there are no shortcuts, and they need to be changing the dialogue around these nations, according to a new report.

The US-based Association of Clinical Research Organizations (ACRO) has joined national grouping the Coalition of Small Business Innovators (CSBI), citing the need to ensure funding for emerging research-intensive companies in the biopharmaceutical and medical device sectors.

Boehringer Ingelheim says it will act promptly to resolve a series of manufacturing complaints highlighted by regulators in the USA concerning violations at its German headquarters.

UK-based contract research organisation (CRO) ClinTec International will formally open an office in Istanbul, Turkey as the company further consolidates its strong presence in the Middle East and North Africa (MENA) region.

Irish drugmaker Elan has once again spurned the advances on Royalty Pharma, despite the latter having upped its bid to $12.50 a share, or around $6.4 billion.

A panel of experts at the US Food and Drug Administration has recommended Merck & Co’s insomnia drug suvorexant when given in lower dosages but rejected the higher dose that the company was seeking.